Market Cap 37.85B
Revenue (ttm) 15.41B
Net Income (ttm) 1.37B
EPS (ttm) N/A
PE Ratio 21.46
Forward PE 20.95
Profit Margin 8.91%
Debt to Equity Ratio 2.38
Volume 616,354
Avg Vol 1,562,576
Day's Range N/A - N/A
Shares Out 170.30M
Stochastic %K 49%
Beta 1.37
Analysts Strong Sell
Price Target $248.10

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions th...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 919 998 2000
Address:
2400 Ellis Road, Durham, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:02 AM
Actionable Trade Alert for $IQV: Market Context: $IQV is currently trading at $222.26, showing a neutral RSI of 46.49, indicating no immediate overbought or oversold conditions. The stock is above its 30-day moving average (MA30) of 220.97 and significantly above its 50-day moving average (MA50) of 216.48, suggesting a bullish trend in the near term. Directional Bias: The price is closer to the 60-day high of 234.3, which may act as a resistance level. The low of 176.16 provides a solid support base. Given the current price action and moving averages, we expect an upward movement towards the high. Trade Plan: - Suggested Entry: $222.50 - Take Profit Targets: 1. $227.50 (2% gain) 2. $232.50 (4.5% gain) 3. $260.00 (17% gain) - Stop Loss: $218.00 (1.1% risk) This plan offers a potential 17% ROI or more at the third target while keeping risk manageable. https://privateprofiteers.com
0 · Reply
lauren_cooper88
lauren_cooper88 Dec. 12 at 5:47 PM
$IQV Mainz Biomed defending $1.00–$1.01 all day with low ~1.00 high ~1.06 and VWAP ~1.027 tells me this is accumulation, then you add DoctorBox bragging 1,000,000+ users and 10,000,000+ results and I’m not ignoring this coil 🚀
0 · Reply
Jerrythemous
Jerrythemous Dec. 12 at 12:03 AM
$IQV green today
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:55 PM
Actionable Trade Alert for $IQV: Market Context: $IQV closed at $224.97, showing resilience above key moving averages (MA30 at $220.74 and MA50 at $216.1). The RSI at 59.67 indicates bullish momentum, nearing overbought territory but not yet overextended. The stock is trading within a 60-day high of $234.3 and a low of $176.16, suggesting potential for upward movement. Directional Bias: Bullish. The stock is above the 30 and 50-day MAs, indicating a strong upward trend. The RSI supports this bullish bias, as it is below the overbought threshold. Trade Plan: - Suggested Entry: $225.00 - Stop Loss: $218.00 (3.5% risk) - Take Profit Targets: 1. $230.00 (2.2% gain) 2. $235.00 (4.5% gain) 3. $263.00 (17% gain) This plan offers a solid risk-reward ratio, capitalizing on the current bullish trend while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:59 AM
Actionable Trade Alert for $IQV: Market Context: $IQV is currently trading at $218.06, situated between its 60-day high of $234.3 and low of $176.16. The RSI at 51.14 indicates a neutral market sentiment, suggesting potential for upward movement as it is neither overbought nor oversold. Directional Bias: The price is above the 30-day moving average (MA30) of $220.34 but below the 50-day moving average (MA50) of $215.02, indicating mixed signals. However, the proximity to the 60D high suggests a bullish potential. Trade Plan: - Suggested Entry: $219.00 - Stop Loss: $212.00 (approx. 3.6% risk) - Take Profit Targets: 1. $225.00 (3% gain) 2. $230.00 (5% gain) 3. $255.00 (16.9% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:46 PM
Actionable Trade Alert for $IQV Market Context: $IQV closed at $223.79, showing strength above its 30-day moving average (MA30) of $220.33 and 50-day moving average (MA50) of $214.28. The RSI at 62.9 indicates bullish momentum but suggests caution as it approaches overbought territory. Directional Bias: The price is trading near the 60-day high of $234.3, indicating potential resistance. However, the upward trend supported by the MAs suggests a continuation of bullish sentiment. Trade Plan: - Suggested Entry: $224.50 (slightly above the last close) - Stop Loss: $218.00 (below MA30 for protection) - Take Profit Targets: 1. Target 1: $230.00 (2.4% gain) 2. Target 2: $235.00 (4.9% gain) 3. Target 3: $262.00 (17.0% gain) With a well-defined risk-reward ratio, this plan allows for a strategic approach to capitalize on upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:47 AM
Actionable Trade Alert for $IQV: Market Context: $IQV closed at $224.92, showing a stable position above its 30-day moving average (MA30) of $220.02 and 50-day moving average (MA50) of $212.41. The RSI at 52.0 indicates a neutral momentum, suggesting potential for upward movement. Directional Bias: The proximity to the 60-day high of $234.3 suggests bullish potential, while the current price is well above the 60-day low of $176.16, indicating a strong support range. The ATR of 5.91 provides insight into volatility, allowing for calculated risk management. Trade Plan: - Suggested Entry: $225.00 - Stop Loss: $218.00 (approx. 3.1% risk) - Take Profit Targets: 1. $230.00 (2.2% ROI) 2. $240.00 (6.7% ROI) 3. $263.00 (17% ROI) The third target aligns with a significant upside potential based on the current market structure. Execute with confidence. https://privateprofiteers.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 4 at 7:15 PM
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 7:09 PM
$VKTX $MEDP $IQV $XBI Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics Biotech stocks, including Viking Therapeutics (VKTX), jumped Thursday on a report that the Food and Drug Administration will soon require just one pivotal study to clinch approval for new medical products. The news could give drug and device approvals a boost, but hurt clinical research organizations like Medpace Holdings (MEDP) and Iqvia Holdings (IQV). The companies are responsible for organizing and running the clinical studies necessary to win regulatory approvals. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/?mod=IBD_FV
0 · Reply
SharePlanner
SharePlanner Dec. 3 at 6:06 PM
Iqvia $IQV doing a great job of holding key support levels on the retest. Strong bounce following a test, hold and bounce off of price level support yesterday. Strong potential for a move back to the upper channel band.
0 · Reply
Latest News on IQV
IQVIA: Increasingly Indispensable In Drug Development

Dec 11, 2025, 1:56 PM EST - 4 days ago

IQVIA: Increasingly Indispensable In Drug Development


Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

Nov 5, 2025, 4:15 PM EST - 5 weeks ago

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors


IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 1:52 PM EDT - 6 weeks ago

IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript


IQVIA Reports Third-Quarter 2025 Results

Oct 28, 2025, 7:00 AM EDT - 6 weeks ago

IQVIA Reports Third-Quarter 2025 Results


IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

Sep 30, 2025, 4:15 PM EDT - 2 months ago

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025


ILMN Stock vs. IQV Stock

Sep 26, 2025, 9:40 AM EDT - 2 months ago

ILMN Stock vs. IQV Stock

ILMN


IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

Sep 11, 2025, 2:00 AM EDT - 3 months ago

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation


IQVIA names Michael Fedock as financial chief

Sep 2, 2025, 9:41 AM EDT - 3 months ago

IQVIA names Michael Fedock as financial chief


IQVIA Announces CFO Transition in Early 2026

Sep 2, 2025, 9:00 AM EDT - 3 months ago

IQVIA Announces CFO Transition in Early 2026


The Big 3: BLDR, IQV, LOW

Aug 19, 2025, 12:00 PM EDT - 4 months ago

The Big 3: BLDR, IQV, LOW

BLDR LOW


IQVIA: Q2 Earnings Exceeded My Expectations

Jul 22, 2025, 5:40 PM EDT - 5 months ago

IQVIA: Q2 Earnings Exceeded My Expectations


IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 2:00 PM EDT - 5 months ago

IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript


IQVIA Reports Second-Quarter 2025 Results

Jul 22, 2025, 7:00 AM EDT - 5 months ago

IQVIA Reports Second-Quarter 2025 Results


IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

Jul 1, 2025, 7:00 AM EDT - 5 months ago

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025


IQVIA Launches New AI Agents for Life Sciences and Healthcare

Jun 11, 2025, 7:00 AM EDT - 6 months ago

IQVIA Launches New AI Agents for Life Sciences and Healthcare


IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?

Jun 10, 2025, 2:23 PM EDT - 6 months ago

IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?


IQVIA Announces Pricing of Senior Notes

Jun 2, 2025, 4:37 PM EDT - 6 months ago

IQVIA Announces Pricing of Senior Notes


IQVIA Announces Offering of Senior Notes

Jun 2, 2025, 8:10 AM EDT - 7 months ago

IQVIA Announces Offering of Senior Notes


IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

May 16, 2025, 8:00 AM EDT - 7 months ago

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials


IQVIA: Q1 Earnings Support Steady Optimism

May 9, 2025, 1:48 PM EDT - 7 months ago

IQVIA: Q1 Earnings Support Steady Optimism


IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript

May 6, 2025, 3:04 PM EDT - 7 months ago

IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript


IQVIA Reports First-Quarter 2025 Results

May 6, 2025, 7:00 AM EDT - 7 months ago

IQVIA Reports First-Quarter 2025 Results


IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

Apr 21, 2025, 4:15 PM EDT - 8 months ago

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025


IQVIA Releases 2024 Sustainability Report

Feb 20, 2025, 10:06 AM EST - 10 months ago

IQVIA Releases 2024 Sustainability Report


IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 11:58 AM EST - 11 months ago

IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:02 AM
Actionable Trade Alert for $IQV: Market Context: $IQV is currently trading at $222.26, showing a neutral RSI of 46.49, indicating no immediate overbought or oversold conditions. The stock is above its 30-day moving average (MA30) of 220.97 and significantly above its 50-day moving average (MA50) of 216.48, suggesting a bullish trend in the near term. Directional Bias: The price is closer to the 60-day high of 234.3, which may act as a resistance level. The low of 176.16 provides a solid support base. Given the current price action and moving averages, we expect an upward movement towards the high. Trade Plan: - Suggested Entry: $222.50 - Take Profit Targets: 1. $227.50 (2% gain) 2. $232.50 (4.5% gain) 3. $260.00 (17% gain) - Stop Loss: $218.00 (1.1% risk) This plan offers a potential 17% ROI or more at the third target while keeping risk manageable. https://privateprofiteers.com
0 · Reply
lauren_cooper88
lauren_cooper88 Dec. 12 at 5:47 PM
$IQV Mainz Biomed defending $1.00–$1.01 all day with low ~1.00 high ~1.06 and VWAP ~1.027 tells me this is accumulation, then you add DoctorBox bragging 1,000,000+ users and 10,000,000+ results and I’m not ignoring this coil 🚀
0 · Reply
Jerrythemous
Jerrythemous Dec. 12 at 12:03 AM
$IQV green today
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:55 PM
Actionable Trade Alert for $IQV: Market Context: $IQV closed at $224.97, showing resilience above key moving averages (MA30 at $220.74 and MA50 at $216.1). The RSI at 59.67 indicates bullish momentum, nearing overbought territory but not yet overextended. The stock is trading within a 60-day high of $234.3 and a low of $176.16, suggesting potential for upward movement. Directional Bias: Bullish. The stock is above the 30 and 50-day MAs, indicating a strong upward trend. The RSI supports this bullish bias, as it is below the overbought threshold. Trade Plan: - Suggested Entry: $225.00 - Stop Loss: $218.00 (3.5% risk) - Take Profit Targets: 1. $230.00 (2.2% gain) 2. $235.00 (4.5% gain) 3. $263.00 (17% gain) This plan offers a solid risk-reward ratio, capitalizing on the current bullish trend while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:59 AM
Actionable Trade Alert for $IQV: Market Context: $IQV is currently trading at $218.06, situated between its 60-day high of $234.3 and low of $176.16. The RSI at 51.14 indicates a neutral market sentiment, suggesting potential for upward movement as it is neither overbought nor oversold. Directional Bias: The price is above the 30-day moving average (MA30) of $220.34 but below the 50-day moving average (MA50) of $215.02, indicating mixed signals. However, the proximity to the 60D high suggests a bullish potential. Trade Plan: - Suggested Entry: $219.00 - Stop Loss: $212.00 (approx. 3.6% risk) - Take Profit Targets: 1. $225.00 (3% gain) 2. $230.00 (5% gain) 3. $255.00 (16.9% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:46 PM
Actionable Trade Alert for $IQV Market Context: $IQV closed at $223.79, showing strength above its 30-day moving average (MA30) of $220.33 and 50-day moving average (MA50) of $214.28. The RSI at 62.9 indicates bullish momentum but suggests caution as it approaches overbought territory. Directional Bias: The price is trading near the 60-day high of $234.3, indicating potential resistance. However, the upward trend supported by the MAs suggests a continuation of bullish sentiment. Trade Plan: - Suggested Entry: $224.50 (slightly above the last close) - Stop Loss: $218.00 (below MA30 for protection) - Take Profit Targets: 1. Target 1: $230.00 (2.4% gain) 2. Target 2: $235.00 (4.9% gain) 3. Target 3: $262.00 (17.0% gain) With a well-defined risk-reward ratio, this plan allows for a strategic approach to capitalize on upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:47 AM
Actionable Trade Alert for $IQV: Market Context: $IQV closed at $224.92, showing a stable position above its 30-day moving average (MA30) of $220.02 and 50-day moving average (MA50) of $212.41. The RSI at 52.0 indicates a neutral momentum, suggesting potential for upward movement. Directional Bias: The proximity to the 60-day high of $234.3 suggests bullish potential, while the current price is well above the 60-day low of $176.16, indicating a strong support range. The ATR of 5.91 provides insight into volatility, allowing for calculated risk management. Trade Plan: - Suggested Entry: $225.00 - Stop Loss: $218.00 (approx. 3.1% risk) - Take Profit Targets: 1. $230.00 (2.2% ROI) 2. $240.00 (6.7% ROI) 3. $263.00 (17% ROI) The third target aligns with a significant upside potential based on the current market structure. Execute with confidence. https://privateprofiteers.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 4 at 7:15 PM
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 7:09 PM
$VKTX $MEDP $IQV $XBI Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics Biotech stocks, including Viking Therapeutics (VKTX), jumped Thursday on a report that the Food and Drug Administration will soon require just one pivotal study to clinch approval for new medical products. The news could give drug and device approvals a boost, but hurt clinical research organizations like Medpace Holdings (MEDP) and Iqvia Holdings (IQV). The companies are responsible for organizing and running the clinical studies necessary to win regulatory approvals. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/?mod=IBD_FV
0 · Reply
SharePlanner
SharePlanner Dec. 3 at 6:06 PM
Iqvia $IQV doing a great job of holding key support levels on the retest. Strong bounce following a test, hold and bounce off of price level support yesterday. Strong potential for a move back to the upper channel band.
0 · Reply
Estimize
Estimize Dec. 3 at 1:09 PM
Wall St is expecting 3.39 EPS for $IQV Q4 [Reporting 02/18 BMO] http://www.estimize.com/intro/iqv?chart=historical&metric_name=eps&utm_cont
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 5:44 PM
Morgan Stanley has adjusted their stance on IQVIA Hldgs ( $IQV ), setting the rating to Overweight with a target price of 250 → 265.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 1 at 10:47 PM
$IQV Current Stock Price: $228.61 Contracts to trade: $230 IQV Dec 19 2025 Call Entry: $3.70 Exit: $5.94 ROI: 60% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 28 at 7:43 PM
$IQV Share Price: $230.83 Contract Selected: May 15, 2026 $230 Calls Buy Zone: $18.61 – $23.00 Target Zone: $32.90 – $40.21 Potential Upside: 67% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 25 at 8:41 PM
$IQV Share Price: $232.34 Contract Selected: May 15, 2026 $230 Calls Buy Zone: $19.89 – $24.57 Target Zone: $36.32 – $44.39 Potential Upside: 72% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Joshua_X
Joshua_X Nov. 25 at 1:31 PM
Life Science Tools — Early Stabilization? Post: Some signs of stabilization in R&D spending. $IQV and $WAT showing relative strength. Keeping $PACB on watch for long-term innovation. Any other life-science names on your radar?
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 22 at 9:13 PM
0 · Reply
RunnerSignals
RunnerSignals Nov. 13 at 9:27 PM
sideways no more $CLBT $BWEN $VGZ $ORLA $IQV all snapped out of their sleepy ranges and popped above their short term averages today
0 · Reply
StockConsultant
StockConsultant Nov. 13 at 2:47 PM
$IQV IQVIA stock, watch for a top of range breakout at https://stockconsultant.com/?IQV
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 10:44 AM
BMO Capital has updated their rating for IQVIA Hldgs ( $IQV ) to Outperform with a price target of 260.
0 · Reply
theflynews
theflynews Nov. 7 at 4:21 PM
Private Markets: Anthropic projects $70B in revenue in 2028 - $IQV - https://thefly.com/permalinks/entry.php/IQVid4234907?1762532330C38
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 5 at 7:40 PM
$IQV Share Price: $210.68 Contract Selected: May 15, 2026 $210 Calls Buy Zone: $19.55 – $24.15 Target Zone: $31.14 – $38.06 Potential Upside: 50% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply